Mr. Corey Giasson reports

MUSTGROW BIOLOGICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING

Mustgrow Biologics Corp. has released the results of its 2026 annual meeting of shareholders, held on June 25, 2026. At the meeting, all director nominees listed in the company's management information circular dated May 28, 2026, were elected by shareholders as directors of the company on a vote held by ballot. The results of the ballot are provided in the attached table.

In addition, shareholders approved the reappointment of Ersnt & Young LLP, chartered professional accountants, as the company's auditor and authorized the directors of the company to fix its remuneration, and approved the company's amended and restated omnibus equity incentive plan. Having received shareholder approval, the omnibus plan remains subject to final approval from the TSX Venture Exchange.

The formal report on voting results with respect to all matters voted upon at the meeting will be filed on SEDAR+ under the company's profile.

About Mustgrow Biologics Corp.

Mustgrow Biologics is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The company's technology is centred on harnessing the natural defence mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, Mustgrow's flagship biofertility product, TerraSante, is registered, organically certified and commercially sold in key agricultural states, including California. Outside of North America, Mustgrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize its wholly owned proprietary products and technologies. The company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 108 issued and pending patents. Mustgrow is publicly traded on the TSX Venture Exchange under the symbol MGRO, and has approximately 70.4 million common shares issued and outstanding, and approximately 91.9 million shares on a fully diluted basis.

We seek Safe Harbor.